Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2279
Título : | Dexmedetomidine, Application in Pediatrics: Paper Review |
Creador: | Perez Guillé, Maria Gabriela |
Nivel de acceso: | Open access |
Palabras clave : | Dexmedetomidina - Farmacología Dexmedetomidina - farmacocinética Dexmedetomidina -líquido cefalorraquídeo Dexmedetomidina -efectos adversos Hipnóticos y Sedantes - farmacocinética Hipnóticos y Sedantes - efectos adversos Analgésicos - farmacocinética Analgésicos - efectos adversos Unidades de Cuidados Intensivos Respiración Artificial - utilización Dexmedetomidine - pharmacology Dexmedetomidine - pharmacokinetics Dexmedetomidine - cerebrospinal fluid Dexmedetomidine - adverse effects Hypnotics and Sedatives - pharmacokinetics Analgesics - pharmacokinetics Analgesics - adverse effects Intensive Care Units Respiration, Artificial - utilization "Dexmedetomidina farmacocinética/farmacodinámica, pacientes pediátricos, reacción adversa, Dexmedetomidine, Pharmacokinetic/pharmacodynamic, Paediatric patients, Adverse reaction, Applications. |
Descripción : | Introduction: Dexmedetomidine is a drug with sedative, hypnotic, and analgesic properties. Its use in adult sedation was approved in 1999. In children, although the use has not been approved, its application by paediatricians is common. The drug offers many advantages in sedative procedures of paediatric patients. First, the half-life is relatively short. Second, it has little or no effect on respiratory management, and lastly, it is well tolerated by intensive care unit patients found with mechanical ventilation. Pharmacokinetics: 93% of the drug bonds with plasma proteins on absorption. Then, it undergoes a rapid phase of distribution with a half-life of 7 min. It has a depuration rate of 15 ml/kg/min, and half-life elimination rate of 2 h. Pharmacodynamics: The drug has antinociceptive action on α-2A adrenergic receptor of the spinal cord. It has hypnotic-sedative action, and inhibitory effect on central noradrenergic transmission. Applications: It is used as a premedication agent with the objective of getting better cooperation of the patient on starting anaesthetic procedures. Adverse reactions: Bradycardia and hypotension. Conclusion: Its use appears to have a promising future in paediatric population; however, it is pertinent that more controlled clinical studies be carried out in order to demonstrate its safety and efficacy. © 2016, Association of Pharmaceutical Teachers of India. All rights reserved. |
Colaborador(es) u otros Autores: | Murata Chiharu Reyes-Reyes Rosa Eugenia Perez Guillé Beatriz Bobadilla-Chavez José Alemon Medina Radames Corral G Ismene Osnaya-Romero Neydi |
Fecha de publicación : | 2016 |
Tipo de publicación: | Revisión |
Formato: | |
Identificador del Recurso : | 10.5530/ijper.50.2.31 |
Fuente: | Indian Journal of Pharmaceutical Education and Research 50(2):S153 - S158 |
URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2279 |
Idioma: | eng |
Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.